BioNTech SE (NASDAQ:BNTX – Free Report) – Equities researchers at HC Wainwright lowered their Q3 2024 earnings per share (EPS) estimates for shares of BioNTech in a research note issued on Monday, October 7th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $0.72 for the quarter, down from their previous forecast of $0.86. HC Wainwright currently has a “Buy” rating and a $150.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($2.87) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.47 EPS, FY2024 earnings at ($3.92) EPS, Q1 2025 earnings at ($2.48) EPS, Q2 2025 earnings at ($2.55) EPS, Q3 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.54 EPS and FY2025 earnings at ($3.88) EPS.
BioNTech (NASDAQ:BNTX – Get Free Report) last issued its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter in the previous year, the firm posted ($0.86) earnings per share. BioNTech’s revenue for the quarter was down 23.3% on a year-over-year basis.
Read Our Latest Stock Analysis on BioNTech
BioNTech Trading Up 0.8 %
Shares of BNTX opened at $118.37 on Wednesday. The firm’s 50-day moving average is $100.13 and its two-hundred day moving average is $93.16. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $28.14 billion, a P/E ratio of 236.74 and a beta of 0.24.
Institutional Trading of BioNTech
Several hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the period. Covestor Ltd increased its stake in BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares during the period. Crewe Advisors LLC acquired a new stake in BioNTech in the 1st quarter worth about $75,000. Finally, American National Bank purchased a new stake in BioNTech in the 1st quarter valued at about $81,000. 15.52% of the stock is owned by hedge funds and other institutional investors.
About BioNTech
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Stories
- Five stocks we like better than BioNTech
- 3 Small Caps With Big Return Potential
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- How to Invest in Biotech Stocks
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- What is a Special Dividend?
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.